肾细胞癌（RCC）基因组的测序确定了一些具有预后意义的突变。癌症基因组图谱研究网络收集的基因组分析显示了明确细胞肾细胞癌（ccRCC）的基因突变和基因表达情况。放射基因组学是一种基于影像表型与疾病基因组学相关性的新的诊断成像领域。最近研究表明P4HA3表达与ccRCC的增加侵袭性、恶预后、增殖、迁移、扩散呈相关性，提示P4HA3可能是ccRCC的预后标志物和治疗靶点。本研究的目的是调查ccRCC患者中P4HA3表达的计算机断层扫描（CT）影像表型。在这个回顾性研究中，我们纳入了196例ccRCC患者，分为两组：P4HA3表达的ccRCC患者（n = 13）和不表达P4HA3的ccRCC患者（n = 183）。在术前CT扫描中评估了几个影像特征。统计学显著性阈值设定为P < .05。我们发现了较大的原发肿瘤大小（P = .033）、肿瘤浸润（P = .023）、不清晰的肿瘤边缘（P = .025）以及进展期肿瘤分期（P = .014）与P4HA3表达之间存在统计学显著性关联。本研究证实了与ccRCC中P4HA3表达相关的CT影像特征。这些结果有助于通过无创方法更好地理解P4HA3表达，并可应用于靶向治疗的开发。版权所有 © 2023. The Association of University Radiologists. Elsevier公司发表。版权所有。

The sequencing of the renal cell carcinoma (RCC) genome identified several mutations with prognostic significance. Genomic analysis, collected in The Cancer Genome Atlas Research Network, revealed several clear cell renal cell carcinoma (ccRCC) gene mutations and gene expressions. Radiogenomics is a new branch of diagnostic imaging based on the association between imaging phenotypes and genomics of diseases. P4HA3 expression has recently been shown to correlate with increased aggressiveness of ccRCC, with poor prognosis, proliferation, migration, invasion, and metastases, suggesting P4HA3 as a prognostic marker and therapeutic target in ccRCC. The aim of this study is to investigate the computed tomography (CT) imaging phenotype of P4HA3 expression in ccRCC patients.In this retrospective study we enrolled 196 ccRCC patients divided into two groups: ccRCC patients with P4HA3 expression (n = 13) and ccRCC patients without P4HA3 expression (n = 183). Several imaging features were evaluated on preoperative CT scan. The statistical significance threshold was set at P < .05.A statistically significant association was found with larger primary tumor size (P = .033), tumor infiltration (P = .023), ill-defined tumor margins (P = .025), and advanced tumor stage American Joint Committee of Cancer (P = .014).This study demonstrates CT imaging features associated with P4HA3 expression in ccRCC. These results could contribute to better understand P4HA3 expression with a noninvasive approach and could be applied to the development of targeted therapies.Copyright © 2023 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.